Gold prices fall as geopolitical tensions ease; U.S. CPI looms
Elevance Health (NYSE:ELV) President and CEO Gail Boudreaux purchased shares of the company’s stock on July 18, 2025, in a series of transactions totaling $2.4 million. The insider buying comes as the healthcare giant’s stock trades near its 52-week low, having declined over 11% in the past week. According to InvestingPro analysis, the stock appears undervalued at its current P/E ratio of 11.7x.
According to a Form 4 filing with the Securities and Exchange Commission, Boudreaux acquired a total of 8,500 shares of Elevance Health common stock in three separate purchases. The prices paid ranged from $286.07 to $287.96 per share.
Specifically, Boudreaux purchased 2,334 shares at a weighted average price of $286.07, 5,116 shares at a weighted average price of $287.12, and 1,050 shares at a weighted average price of $287.96.
Following these transactions, Boudreaux directly owns 151,020 shares of Elevance Health. She also indirectly owns 60 shares held in a spouse’s revocable trust.
In other recent news, Elevance has faced several adjustments and evaluations following its second-quarter earnings report. The company reported earnings per share of $8.84, a 12.6% decline year-over-year and $0.14 below consensus estimates, prompting UBS to lower its price target to $435 while maintaining a Buy rating. Elevance also reduced its full-year 2025 earnings per share guidance to $30, down from its previous range of $34.15 to $34.85. Guggenheim, maintaining a Buy rating, also lowered its price target to $360, citing cost pressures in Medicaid and the Health Insurance Exchange market. Meanwhile, BofA Securities adjusted its price target to $350, pointing to concerns in exchanges and Medicaid, while keeping a Neutral rating. Cantor Fitzgerald reiterated an Overweight rating with a $400 price target, expressing concerns about the challenges in achieving the newly lowered 2025 guidance. On the other hand, Leerink Partners downgraded Elevance to Market Perform, significantly reducing its price target to $310 due to growth concerns and limited upside potential. Despite these challenges, analysts noted opportunities for Elevance in segments like Medicare Advantage, though uncertainties remain.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.